secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059008
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q3 product revenue $57.8M (up 244% YoY); Auvelity sales $37.7M
---------------------------------------------------------------------

- Total Q3 product revenue was $57.8M vs $16.8M in Q3 2022; Auvelity net sales $37.7M (36% sequential growth).
- Sunosi net product revenue $20.1M, up 20% YoY; total net loss of $62.2M ($1.32 per share) vs $44.8M loss in Q3 2022.
- Cash and equivalents of $416.6M at Sept 30, 2023; shares outstanding 47.3M.
- Pipeline on track: AXS-12 narcolepsy Phase 3 top-line expected Q1 2024; AXS-07 migraine NDA resubmission and AXS-14 fibromyalgia NDA submission both targeted H1 2024.
- Auvelity sales force expanding from 162 to 260 representatives; payer coverage ~70% of covered lives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/0000950170-23-059008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023059008/axsm-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer